Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04049383 · ClinicalTrials.gov registry record · Phase 1
CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL
A Phase 1 study, sponsored by Medical College of Wisconsin.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT04049383 is a Phase 1 study that was terminated before completion, run by Medical College of Wisconsin. The registered enrollment target is 5 participants.
The verdict
NCT04049383, a Phase 1 study, was terminated before completion, sponsored by Medical College of Wisconsin.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This phase 1 study will evaluate the safety and efficacy of a CAR-T cell therapy directed against two B cell antigens (CD19 CD20) and produced under good manufacturing practice (GMP) conditions using the closed system CliniMACS Prodigy device in B ALL.
Interventions
- BIOLOGICAL CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)
- BIOLOGICAL CAR-20/19-T cells (5 x 10^5 CAR-20/19-T cells/kg)
- BIOLOGICAL CAR-20/19-T cells (1 x10^6 CAR-20/19-T cells/kg)
- BIOLOGICAL CAR-20/19-T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-10-16 |
| Est. Completion | 2025-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04049383
The ClinicalTrials.gov registry entry for NCT04049383 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg) is the first listed.
NCT04049383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04049383 about?
NCT04049383 is a clinical study titled "CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL". This phase 1 study will evaluate the safety and efficacy of a CAR-T cell therapy directed against two B cell antigens (CD19 CD20) and produced under good manufacturing practice (GMP) conditions using the closed system CliniMACS Prodigy device in B ALL.
What is the current status of trial NCT04049383?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2020-10-16. Estimated completion is 2025-09-01.
What interventions are being tested in trial NCT04049383?
The interventions under investigation include: CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg) (BIOLOGICAL), CAR-20/19-T cells (5 x 10^5 CAR-20/19-T cells/kg) (BIOLOGICAL), CAR-20/19-T cells (1 x10^6 CAR-20/19-T cells/kg) (BIOLOGICAL), CAR-20/19-T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04049383?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.